ArticleJournal of cytology
Validating the Utility of the Milan System of Reporting Salivary Gland Cytopathology for the Diagnosis of Salivary Gland Fine-Needle Aspirates in a North Indian Tertiary Care Center and Comparing the Risk of Malignancy with its Two Editions.
Article in Journal of cytology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Salivary gland (SG) fine-needle aspiration (FNA) is a well-accepted tool for preoperative management of salivary gland lesions (SGLs). First and second editions of the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) were published in the years 2018 and 2023, respectively. The MSRSGC aims to improve patient care by providing better communication between clinicians and institutions. It has six ascending diagnostic categories having a definite risk of malignancy (ROM) and corresponding management schema. Our study assessed the incidence and corresponding ROM of each MSRSGC category within a tertiary care northern India referral center and compared each ROM with those laid down in the two editions of the MSRSGC. Aims and Objectives: The main aims and objectives are as follows:1. Validating the utility of the MSRSGC for the diagnosis of SG-FNAs in a North Indian Tertiary Care Center.2. Comparing the Risk of Malignancy with its Two Editions. Materials and Methods: Data on SG-FNAs performed between 01.01.2010 and 31.03.2024 were searched from the hospital information system. The cytopathology and histopathological slides were retrieved, and each case was separately reviewed and retrospectively classified into the I) non-diagnostic (ND), II) non-neoplastic (NN), III) atypia of undetermined significance (AUS), IVA) benign neoplasms (NB), IVB) SG neoplasm of uncertain malignant potential (SUMP), V) suspicious for malignancy (SFM), or VI) malignant categories according to the MSRSGC. Cyto-histopathological correlation analysis was performed, and the ROM for each category was calculated. Results: A total of 793 such cases were obtained. Histopathological follow-up was available in 267 cases, which included 2 (0.7%) ND, 29 (10.9%) NN, 5 (1.9%) AUS, 190 (71.2%) NB, 11 (4.1%) SUMP, 10 (3.7%) SFM, and 20 (7.5%) malignant cases. The calculated ROM for these ascending categories were 0%, 27.6%, 60%, 11.8%, 45.5%, 90%, and 100%, respectively. Conclusion: MSRSGC is a valuable means to standardize the reporting and preoperatively stratify SGLs as per the ROM for each ascending risk category. This study, to the best of our knowledge, is the largest Indian study to authenticate the utility and reproducibility of the MSRSGC in our tertiary care institute.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.